GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Corbus Pharmaceuticals Holdings Inc (LTS:0SZI) » Definitions » Total Premiums Earned

Corbus Pharmaceuticals Holdings (LTS:0SZI) Total Premiums Earned


View and export this data going back to 2018. Start your Free Trial

What is Corbus Pharmaceuticals Holdings Total Premiums Earned?

Total Premiums Earned only applies to insurance companies.


Corbus Pharmaceuticals Holdings (LTS:0SZI) Business Description

Traded in Other Exchanges
Address
500 River Ridge Drive, Norwood, MA, USA, 02062
Corbus Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics for endocannabinoid or immune systems. The company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus. Corbus' internal development pipeline includes CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload and CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells.